Trevena to Present at the 16th Annual BIO CEO & Investor Conference

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company and a leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., president and chief executive officer of Trevena, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:00 a.m. ET in New York City.

To access a live audio webcast of the presentation, please visit the “Investors” section at www.trevenainc.com. The webcast will be archived for 90 days.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. In addition to TRV734, Trevena has applied its proprietary product platform to identify and advance two other differentiated product candidates into the clinic -- TRV027 to treat acute heart failure, and TRV130 to treat moderate to severe acute pain intravenously. Trevena also plans to advance additional preclinical product candidates.

Investor Contacts:
Trevena, Inc.
Roberto Cuca
Senior vice president and chief financial officer
610-354-8840 x224
rcuca@trevenainc.com
or
Argot Partners
Andrea Rabney
President and chief executive officer
212-600-1902
andrea@argotpartners.com
or
Media Contact:
Argot Partners
Eliza Schleifstein
917-763-8106
eliza@argotpartners.com

Source: Trevena, Inc.

Released February 4, 2014